This study aimed to design and synthesize new Schiff base ligands and their Fe(III) complexes that integrate a redox-active Fe(III) center with a dopaminergic pharmacophore to achieve combined redox and receptormediated anticancer effects. A five-step synthetic route was employed to obtain the target compounds, followed by spectroscopic characterization using FTIR, 1H/13C NMR, MS, and elemental analysis. The cytotoxic activity of the compounds was evaluated against U87MG glioblastoma cells using the MTT assay, and molecular docking simulations were performed with the D2 dopamine receptor (PDB ID: 6CM4) to rationalize the observed structure-activity relationships. The compounds exhibited IC50 values ranging from 3.09 to 111.6 mu M, with Ligand 18 and Complex 27 showing the highest antiproliferative activity (3.09 and 3.31 mu M, respectively). Docking studies revealed strong binding affinities (Delta G = -5.9 to -6.9 kcal mol-1) and key interactions with Asp114, Tyr408, and Trp386 residues of DRD2. These findings suggest that Fe(III) coordination modulates lipophilicity, binding topology, and redox behavior, leading to enhanced cytotoxicity in a compound-dependent manner. Overall, the results highlight the potential of dopamine-Fe(III) Schiff bases as redox-active, receptortargeted antiglioblastoma candidates.